Lumosa Therapeutics Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 16.27 million compared to TWD 4.59 million a year ago. Net loss was TWD 119.92 million compared to TWD 154.65 million a year ago. Basic loss per share from continuing operations was TWD 0.74 compared to TWD 0.95 a year ago. Diluted loss per share from continuing operations was TWD 0.74 compared to TWD 0.95 a year ago.
For the nine months, sales was TWD 38.45 million compared to TWD 12.29 million a year ago. Net loss was TWD 125.53 million compared to TWD 534.3 million a year ago. Basic loss per share from continuing operations was TWD 0.77 compared to TWD 3.29 a year ago. Diluted loss per share from continuing operations was TWD 0.77 compared to TWD 3.29 a year ago.